Neurelis, Inc., recently announced the commercial availability of VALTOCO® (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in adult and pediatric patients 6 years of age and older.
VALTOCO is a proprietary formulation of diazepam incorporating the science of Intravail®, a proprietary transmucosal absorption enhancer. In a long-term, open-label, repeat dose, clinical trial, the safety of VALTOCO was evaluated and more than 4,000 seizure were treated. VALTOCO was generally safe and well tolerated during clinical studies. The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.
For more information, read the full press release here.